Cargando…
Synergistic effect of receptor-interacting protein 140 and simvastatin on the inhibition of proliferation and survival of hepatocellular carcinoma cells
Hepatocellular carcinoma is the sixth most prevalent malignant tumor and the third most common cause of cancer-associated mortality. Statins have been investigated for carcinoma prevention and treatment. In addition, receptor-interacting protein 140 (RIP140) has been observed to inhibit the Wnt/β-ca...
Autores principales: | Xia, Kun, Zhang, Panpan, Hu, Jian, Hou, Huan, Xiong, Mingdi, Xiong, Junping, Yan, Nianlong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835881/ https://www.ncbi.nlm.nih.gov/pubmed/29541202 http://dx.doi.org/10.3892/ol.2018.7831 |
Ejemplares similares
-
miR-33 and RIP140 participate in LPS-induced acute lung injury
por: LI, Hua, et al.
Publicado: (2019) -
Endoplasmic Reticulum Stress Affects Cholesterol Homeostasis by Inhibiting LXRα Expression in Hepatocytes and Macrophages
por: Wang, Tian, et al.
Publicado: (2020) -
Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells
por: Steinmetz, Martin, et al.
Publicado: (2010) -
Simvastatin promotes endothelial dysfunction by activating the Wnt/β-catenin pathway under oxidative stress
por: He, Zhiqiang, et al.
Publicado: (2019) -
Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice
por: Lee, Bok-Soo, et al.
Publicado: (2012)